Improved home BP profile with dapagliflozin is associated with amelioration of albuminuria in Japanese patients with diabetic nephropathy: the Yokohama add-on inhibitory efficacy of dapagliflozin on albuminuria in Japanese patients with type 2 diabetes study (Y-AIDA study)

Table 4 Multivariate linear regression analysis of factors associated with the change in log-UACR

	B	SE	β	P value
Change in morning home SBP (mmHg)	0.01626	0.00733	0.26330	0.0305
Diabetes duration (year)	− 0.02156	0.01236	− 0.24438	0.0867
Fasting blood sugar (mg/dL)	− 0.00332	0.00219	− 0.17868	0.1353
Change in office SBP (mmHg)	0.00668	0.00482	0.17351	0.1712
HbA1c (%)	− 0.22415	0.16215	− 0.18777	0.1723
WBC (/mm³)	0.00005302	0.00005094	0.14462	0.3025
Change in body weight (kg)	0.04017	0.04919	0.11133	0.4176
Change in HbA1c (%)	− 0.04314	0.16195	− 0.03561	0.7909
Change in d-ROMs (CARR U)	0.00057766	0.00244	0.03157	0.8141

Adjusted R² = 0.1942, P = 0.01. Variables included in the model were changes in morning home SBP, office SBP, body weight, HbA1c, and d-ROMs, and baseline values of diabetes duration, fasting blood sugar, HbA1c, and WBC
B regression coefficient, SE standard error, β standardized regression coefficient, SBP systolic blood pressure, HbA1c glycated hemoglobin, WBC white blood cell, d-ROMs diacron-reactive oxygen metabolites

ISSN: 1475-2840